In recent conversations with experts in epilepsy, the impact of stigmatization remains high for patients and ongoing efforts by clinicians to address this issue in the clinical setting has been underscored, despite the global lack of awareness about new treatments and other resources.
SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders and oncology, will present data on cenobamate at the American Epilepsy Society (AES) Annual Meeting, to be held December 1-5, 2023, in Orlando, Florida.
email article
The FDA on Wednesday updated its warning about potential increased arrhythmia risk in people with cardiac disease who are taking the seizure and mental health drug lamotrigine (Lamictal) with new data.
In October 2020, the FDA added information about arrhythmia risk to lamotrigine s prescribing information and medication guides based on
in vitro studies. Now the agency says it wants to evaluate whether other medicines in the same drug class have similar effects and is requiring safety studies on those drugs, also. Other sodium channel blockers approved for epilepsy, bipolar disorder, and other indications should not be considered safer alternatives to lamotrigine in the absence of additional information, the FDA said. The agency s statement included a list of 10 such agents, including carbamazepine, phenytoin, and topiramate, for which postmarket studies must be conducted.